BioAtla (BCAB) News Today $0.50 +0.01 (+2.13%) Closing price 04:00 PM EasternExtended Trading$0.50 0.00 (-0.18%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period JMP Securities Downgrades BioAtla (BCAB)August 14, 2025 | msn.comBioAtla downgraded to Market Perform from Outperform at Citizens JMPAugust 13, 2025 | msn.comBioAtla’s Earnings Call: Positive Clinical Progress Amid Financial ChallengesAugust 13, 2025 | msn.comBioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comBioAtla, Inc. (BCAB) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | seekingalpha.comBioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent ProgressAugust 8, 2025 | finance.yahoo.comBioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025August 4, 2025 | globenewswire.comBioAtla Stock Short Interest Report | NASDAQ:BCAB - BenzingaJuly 29, 2025 | benzinga.comBioAtla, Inc. (BCAB) latest stock news and headlines - Yahoo FinanceJuly 18, 2025 | uk.finance.yahoo.comBioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia MeetingJuly 17, 2025 | globenewswire.comBioAtla Reports Encouraging Preliminary Results from Phase 1 Study of BA3182 in Heavily Pretreated Metastatic Adenocarcinoma Patients - NasdaqJuly 5, 2025 | nasdaq.comBioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers CongressJuly 3, 2025 | globenewswire.comBCAB - BioAtla Inc Ordinary Shares Ownership - MorningstarJuly 1, 2025 | morningstar.comMBioAtla Approves 2025 Corporate Bonus PlanJune 20, 2025 | tipranks.comBioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma ...June 3, 2025 | morningstar.comMBioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025June 2, 2025 | msn.comBioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimenJune 2, 2025 | globenewswire.comBioAtla Receives Nasdaq Non-Compliance NoticeMay 16, 2025 | tipranks.comBioAtla at Citizens JMP Life Sciences: Strategic Partnerships in FocusMay 9, 2025 | investing.comBioAtla, Inc. (BCAB) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comBioAtla Reports First Quarter 2025 Financial Results and Highlights Recent ProgressMay 6, 2025 | globenewswire.com7BCAB : A Preview Of BioAtla's EarningsMay 5, 2025 | benzinga.comBioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025May 1, 2025 | seekingalpha.comBioAtla to Participate in the Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comBioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025April 29, 2025 | globenewswire.comBioAtla announces poster presentations at 2025 AACR meetingApril 24, 2025 | markets.businessinsider.comBioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual MeetingApril 24, 2025 | globenewswire.comBioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2025 | globenewswire.comH.C. Wainwright Keeps Their Hold Rating on BioAtla (BCAB)March 31, 2025 | markets.businessinsider.comBioAtla price target lowered to $1 from $5 at Citizens JMPMarch 31, 2025 | markets.businessinsider.comBioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comEarnings call transcript: BioAtla Q4 2024 sees strategic cost cuts, stock risesMarch 28, 2025 | uk.investing.comBioAtla price target lowered to $10 from $13 at BTIGMarch 28, 2025 | markets.businessinsider.comBioAtla announces restructuring, to cut over 30% of workforceMarch 28, 2025 | markets.businessinsider.comBioAtla, Inc. (BCAB) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comBioAtla Cuts 30% of Jobs in Restructuring EffortMarch 27, 2025 | marketwatch.comBioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent ProgressMarch 27, 2025 | globenewswire.comEarnings Outlook For BioAtlaMarch 27, 2025 | benzinga.comBioAtla Announces Two Poster Presentations at Upcoming Medical MeetingsMarch 20, 2025 | globenewswire.comBioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025March 19, 2025 | globenewswire.comAXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)March 4, 2025 | globenewswire.comBioAtla faces Nasdaq delisting over share price ruleFebruary 8, 2025 | msn.comBioAtla Secures $9.2M for Clinical Program AdvancementsDecember 20, 2024 | markets.businessinsider.comBioAtla Highlights Advancements in CAB Cancer TherapyDecember 20, 2024 | markets.businessinsider.comBioAtla to sell 9.68M shares at 95.2c in registered direct offeringDecember 20, 2024 | markets.businessinsider.comBioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection PointsDecember 20, 2024 | globenewswire.comBioAtla presents data on mecbotamab vedotin in advanced NSCLCDecember 17, 2024 | markets.businessinsider.comBioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 16, 2024 | globenewswire.comBioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science MeetingDecember 10, 2024 | globenewswire.comGSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB)November 19, 2024 | marketbeat.com Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCAB Media Mentions By Week BCAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAB News Sentiment▼0.000.70▲Average Medical News Sentiment BCAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAB Articles This Week▼01▲BCAB Articles Average Week Get the Latest News and Ratings for BCAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for BioAtla and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies HLVX News SRZN News ONCY News IOBT News EQ News ANEB News VTGN News TCRX News PLRX News ADAG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAB) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is hereWashington just added $1 trillion to the national debt in less than two months — an astonishing pace of spendi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
